Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $480.85, generating approximately $4.57 million. Her direct ownership fell 2.84% to 324,443 shares.
- United Therapeutics beat quarterly earnings expectations, reporting $7.27 in EPS versus the $6.86 consensus, though revenue declined 1.9% year over year to $783.3 million.
- Analysts maintain a “Moderate Buy” consensus with an average price target of $621, despite mixed individual views; institutional investors and hedge funds own 94.08% of the company.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $480.85, for a total transaction of $4,568,075.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company's stock, valued at $156,008,416.55. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
United Therapeutics Stock Performance
Shares of United Therapeutics stock opened at $481.47 on Wednesday. The firm's 50-day simple moving average is $508.90 and its 200-day simple moving average is $539.33. United Therapeutics Corporation has a twelve month low of $409.07 and a twelve month high of $609.35. The firm has a market cap of $20.65 billion, a P/E ratio of 17.23, a price-to-earnings-growth ratio of 2.43 and a beta of 0.56.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to analysts' expectations of $804.65 million. During the same quarter in the previous year, the firm posted $6.41 earnings per share. The firm's revenue for the quarter was down 1.9% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics Corporation will post 26.21 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
UTHR has been the topic of several analyst reports. Bank of America lowered their price objective on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. JPMorgan Chase & Co. raised their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Royal Bank Of Canada decreased their price target on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research note on Thursday, August 6th. Morgan Stanley set a $515.00 price target on United Therapeutics in a research report on Thursday, August 6th. Finally, The Goldman Sachs Group began coverage on United Therapeutics in a research note on Thursday, September 24th. They set a "sell" rating and a $321.00 price objective for the company. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $621.00.
Check Out Our Latest Report on United Therapeutics
Institutional Trading of United Therapeutics
Hedge funds have recently modified their holdings of the company. Toth Financial Advisory Corp grew its position in United Therapeutics by 2,400.0% during the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company's stock worth $27,000 after acquiring an additional 48 shares during the last quarter. Fiduciary Financial Advisors acquired a new stake in United Therapeutics during the 2nd quarter valued at $30,000. Caitlin John LLC bought a new position in United Therapeutics in the 2nd quarter valued at $37,000. International Assets Investment Management LLC raised its position in United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 64 shares during the last quarter. Finally, Keating Financial Advisory Services Inc. bought a new position in United Therapeutics in the 2nd quarter valued at $81,000. Institutional investors and hedge funds own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company's products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.
United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
